Safety and efficacy of nivolumab for non-clear cell kidney cancer
Nivolumab alone and in combination with ipilimumab is used for the treatment of [...]
Clinical outcomes of first-line sunitinib followed by immunotherapy
A recent study published in Clinical Genitourinary Cancer has found [...]
Managing cancer patients during the COVID-19 pandemic
The European Society for Medical Oncology (ESMO) has released a [...]
Potential rise in the incidence of kidney cancer in children
Wilms tumour is the most common type of kidney cancer [...]
Survival outcomes for patients on ipilimumab plus nivolumab combination therapy
Further results from the ongoing CheckMate 214 phase III study [...]
Immune checkpoint inhibitors for papillary kidney cancer
Papillary renal cell carcinoma (RCC) is a rare form of [...]
COVID-19 outcomes with anticancer treatments
There is a lot of ongoing research to understand the [...]
NHS rolls out ‘COVID-friendly’ cancer treatments
NHS chief executive, Sir Simon Stevens has announced the roll-out [...]
First-line treatment of patients with sarcomatoid kidney cancer
Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive [...]
Survivorship and immune checkpoint inhibitors
In a study reported in the August issue of the [...]
